Moreover, several myostatin modulators have already reached clinical trial phase for a broad range of indications, including muscular dystrophy, sporadic inclusion body myositis (IBM), cachexia, aging-related muscle atrophy, obesity, type 2 diabetes, and SMA [102–113]. This evidence concerns the gene MSTN and type 2 diabetes mellitus.